Michel Vounatsos vs Antony Mattessich

Michel Vounatsos

CEO of Biogen

BIO: Mr. Michel Vounatsos has been the Chief Executive Officer of Biogen Inc. since January 6, 2017. Mr. Vounatsos served as the Chief Commercial Officer and Executive Vice President of Biogen Inc. since April 18, 2016 until December 2016. He is a sophisticated global business leader who has a track record of commercial success and creativity. He joined Biogen after a 20 year career at Merck, where he various positions including served as president, Primary Care Business Line and Merck Customer Centricity. Prior to this role, he held leadership positions at Merck across Europe and in China. He has been Director of Biogen Inc. since January 6, 2017. Mr. Vounatsos attended the Universite Victor Segalen, Bordeaux II, in France, receiving his C.S.C.T. certificate in Medicine. He received his M.B.A. from the HEC School of Management in Paris.

Antony Mattessich

CEO of Ocular Therapeutix

BIO: Mr. Antony Mattessich has been the Chief Executive Officer and President of Ocular Therapeutix, Inc. since August 1, 2017. Mr. Mattessich serves as Managing Director of Mundipharma International Limited. He served as Regional Director of Europe Operations at Mundipharma International Limited. He has wealth of experience to Ocular Therapeutix, having held leadership roles for a number of global pharmaceutical companies across the US, Europe and Asia, including Novartis, Bristol Meyers Squibb and Merck & Co. Over the course of his career, Mr. Mattessich has developed expertise across multiple disciplines, including general management, global marketing, new product planning, R&D and business development. Mr. Mattessich was the Managing Director of one of the world's largest privately-owned pharmaceutical companies, Mundipharma. He has been a Director of Ocular Therapeutix, Inc. since June 22, 2017. He holds a Master's Degree in International Affairs from Colombia University and a Bachelor of Arts from University of California, Berkeley.